AbbVie Inc. has its second positive readout of Phase III data for its Parkinson’s disease candidate tavapadon this year, but is waiting for data from a third study before determining its filing plans for the drug, a selective D1/D5 receptor partial agonist being studied as a new mechanism for the treatment of Parkinson’s.
Key Takeaways
-
With success in the first of two Phase III monotherapy studies of Parkinson’s candidate tavapadon, AbbVie may be able to bring a new mechanism of action to treatment of the neurodegenerative disease.
-
Acquired in last year’s buyout of Cerevel, tavapadon also demonstrated efficacy as adjunctive therapy to levodopa in Phase III data reported in April
In the Phase III TEMPO-1 monotherapy trial, two fixed daily doses of tavapadon – 5mg and 15mg – met the primary endpoint of reduction (improvement) from baseline in Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) at 26 weeks. The lower dose yielded a 9.7-point reduction and the higher dose a 10.2-point reduction versus a 1